Larry Ereshefsky

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. ncbi Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic
    L Ereshefsky
    College of Pharmacy, The University of Texas at Austin, USA
    J Clin Psychiatry 60:20-30. 1999
  2. ncbi Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system
    Larry Ereshefsky
    California Clinical Trials, Glendale, California 91206, USA
    Drugs R D 6:129-37. 2005
  3. ncbi Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics
    Larry Ereshefsky
    Department of Pharmacology, University of Texas Health Science Center at San Antonio and Clinical Research Unit, San Antonio State Hospital, 78229, USA
    J Clin Psychiatry 64:18-23. 2003
  4. ncbi Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine
    L Ereshefsky
    College of Pharmacy, University of Texas at Austin, USA
    Depress Anxiety 12:30-44. 2000
  5. ncbi Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
    Y W Francis Lam
    Department of Pharmacology, University of Texas Health Science Center at San Antonio, USA
    J Clin Pharmacol 43:1274-82. 2003
  6. ncbi Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications
    Dawn I Velligan
    University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Psychiatr Serv 54:665-7. 2003
  7. ncbi The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia
    Dawn I Velligan
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Schizophr Bull 34:483-93. 2008
  8. ncbi Relationships among subjective and objective measures of adherence to oral antipsychotic medications
    Dawn I Velligan
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Psychiatr Serv 58:1187-92. 2007
  9. ncbi Defining and assessing adherence to oral antipsychotics: a review of the literature
    Dawn I Velligan
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Schizophr Bull 32:724-42. 2006
  10. ncbi The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update
    Alexander L Miller
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 65:500-8. 2004

Collaborators

Detail Information

Publications17

  1. ncbi Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic
    L Ereshefsky
    College of Pharmacy, The University of Texas at Austin, USA
    J Clin Psychiatry 60:20-30. 1999
    ..Further study is warranted to determine loxapine's place in our treatment of schizophrenia...
  2. ncbi Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system
    Larry Ereshefsky
    California Clinical Trials, Glendale, California 91206, USA
    Drugs R D 6:129-37. 2005
    ....
  3. ncbi Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics
    Larry Ereshefsky
    Department of Pharmacology, University of Texas Health Science Center at San Antonio and Clinical Research Unit, San Antonio State Hospital, 78229, USA
    J Clin Psychiatry 64:18-23. 2003
    ..Consistent with other long-acting medications, plasma drug level fluctuation is reduced more with long-acting than with oral risperidone. Analyses are currently underway to further examine safety outcomes with long-acting risperidone...
  4. ncbi Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine
    L Ereshefsky
    College of Pharmacy, University of Texas at Austin, USA
    Depress Anxiety 12:30-44. 2000
    ....
  5. ncbi Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
    Y W Francis Lam
    Department of Pharmacology, University of Texas Health Science Center at San Antonio, USA
    J Clin Pharmacol 43:1274-82. 2003
    ..These results suggest that caution with the use of midazolam is warranted with potent CYP3A4 inhibitors...
  6. ncbi Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications
    Dawn I Velligan
    University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Psychiatr Serv 54:665-7. 2003
  7. ncbi The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia
    Dawn I Velligan
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Schizophr Bull 34:483-93. 2008
    ..Comprehensive supports targeting multiple domains of functioning are necessary to improve functional outcomes. Maintenance of gains in functional outcome may require some form of continued intervention...
  8. ncbi Relationships among subjective and objective measures of adherence to oral antipsychotic medications
    Dawn I Velligan
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Psychiatr Serv 58:1187-92. 2007
    ..This prospective study examined the agreement among measures of adherence to oral antipsychotic medications among 52 outpatients with schizophrenia...
  9. ncbi Defining and assessing adherence to oral antipsychotics: a review of the literature
    Dawn I Velligan
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Schizophr Bull 32:724-42. 2006
    ..The suggestions are designed to advance the field with respect to both understanding predictors of adherence and developing interventions to improve adherence to oral antipsychotic medications...
  10. ncbi The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update
    Alexander L Miller
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 65:500-8. 2004
    ..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators...
  11. ncbi Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan
    Larry Ereshefsky
    California Clinical Trials, PAREXEL International, Glendale, California, USA
    CNS Spectr 14:1-8. 2009
    ..Resources for clinicians include internet databases, software programs, package inserts, and consultation with pharmacists...
  12. ncbi The 6-month persistence on SSRIs and associated economic burden
    Larry Ereshefsky
    California Clinical Trials, Glendale, California, USA
    J Med Econ 13:527-36. 2010
    ..To assess persistence on SSRIs (most prescribed antidepressants) and associated healthcare costs in a naturalistic setting...
  13. ncbi CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6
    Y W Francis Lam
    Department of Pharmacology, University of Texas Health Science Center at San Antonio, 78284 6220, USA
    Pharmacotherapy 22:1001-6. 2002
    ..To assess the correlation between plasma concentrations of four commonly administered selective serotonin reuptake inhibitors (SSRIs) and the magnitude of cytochrome P450 (CYP) 2D6 inhibition...
  14. ncbi Clinical guidelines: Dosing and switching strategies for long-acting risperidone
    Stephen R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    J Clin Psychiatry 64:41-6. 2003
  15. ncbi Antidepressant drug-drug interaction profile update
    Larry Ereshefsky
    University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Drugs R D 6:323-36. 2005
    ....
  16. ncbi QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study
    Lu Zhang
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol 49:146-53. 2007
    ..The electrophysiological effects of duloxetine at supratherapeutic exposures were evaluated to ensure compliance with regulatory criteria and to assess the QT prolongation potential...
  17. ncbi The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate
    Michael A Derby
    Eli Lilly and Company, Indianapolis, IN, USA
    J Cardiovasc Pharmacol 49:384-93. 2007
    ..Overall, the types of adverse events reported in this study were similar to those in other studies of duloxetine in healthy subjects...